🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Patients with ESR1 mutations who received 12 months or more of prior treatment with a CDK4/6 inhibitor achieved a median PFS of 8.61 months with elacestrant compared with 1.91 months for those given SOC #oncology #nursing #bcsm #ASCO23 ow.ly/3cUS50OOBbj

The new guidelines indicate that blood-based ctDNA testing is preferred due to greater sensitivity. Guardant360® CDx test is the only FDA-approved CDx to identify patients with ESR1 mutations who may benefit from treatment with ORSERDU™ (elacestrant). bit.ly/3Jm8r5l

Amazing weekend in Kona at the 1st annual #DAVAHawaiiBreast 🌸 Summit hosted by DAVA Oncology. Superstar faculty 🤩 and gorgeous setting. Proud to be part of the Menarini Stemline US Regional Marketing Team Susan Bergen @mollyhollman3 Jennifer Whipkey Julia Bolduc

Discover a treatment option for metastatic breast cancer. Watch the on-demand broadcast to learn about when and how to test for an ESR1 mutation. bit.ly/3QVOczU

🛎️ Our latest "Ask the Expert" webinar is happening soon! Learn about ESR1 mutations from Dr. Anne O’Dea, Medical Director of Breast Cancer Survivorship and Breast Cancer Clinical Research Program Services @UnivofKansas Medical Center: bit.ly/3sHSEZ7

.@eu_commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer G Curigliano MD PhD #bcsm bit.ly/3PLBS4f

Sheila Johnson, living with #metastaticbreastcancer for 13 years, veteran, and clinical trial participant advocates for #clinicaltrials becoming standard of care and we all "get online, get involved, research, ask questions." youtu.be/IKcxdEe2FqE #bcam

A hauntingly beautiful essay. Also a testament to how deeply oncology pharmacists are committed to improving the lives of patients ❤️

Thrilled to represent Menarini Stemline at my 9th SABCS and favorite meeting to date!

At Menarini Stemline, our team is focused on bringing transformational oncology treatments to people living with cancer globally. Today, on World Cancer Day, we are proud to stand with the global community of individuals, families, and communities affected by cancer. Read more:

Menarini Group presents updated data from combination studies of their treatment in patients with ER+, HER2- metastatic breast cancer at the ASCO 2024 annual meeting. Read today’s press release here: bit.ly/3WNXYXU

The Menarini Stemline team is excited to connect with the breast cancer community at the San Antonio Breast Cancer Symposium this week! Be sure to visit our booth as we share our latest updates as we continue our work to bring transformational oncology treatments to individuals

Our team had an incredible experience connecting with the oncology community at #SABCS24 and sharing our latest updates for individuals living with breast cancer. We are looking forward to continuing our work to help improve outcomes for the patient community!

We are honored to announce that our oncology treatment has been awarded “Excellence in Life Science” in the category “Best Innovative Drug of the Year 2024” at the Life Science Excellence Awards 2024 edition! This prestigious award, promoted by the Italian Society HOMNYA,

Join Menarini Stemline at the Miami Breast Cancer Conference! Visit us at both booths #24 and #52 to learn more about our latest advancements in breast cancer. We look forward to connecting with you. #BreastCancer #MBCC25

Our team just wrapped up at the recent 42nd Annual Miami Breast Cancer Conference, where experts gathered to share advancements in breast cancer research, treatment, and patient care. We look forward to continuing our work to help patients across the globe! #BreastCancer

Menarini Group presents updated data underscoring the combinability of their treatment in patients with ER+, HER2- metastatic breast cancer (mBC) at the ASCO 2025 annual meeting. Read today’s press release here: bit.ly/3ZuZuP3

This is an extraordinary interview. Dr MacDonald’s grace, eloquence, and wisdom are truly inspiring. A worthwhile listen!

The Menarini Stemline team is in Chicago this week to join the oncology community at #ASCO25. If you’re onsite, be sure to visit our booths to learn more about our focus on bringing transformational oncology treatments to individuals living with cancer.

Our team had an energizing few days in Chicago at #ASCO25! We are looking forward to continuing to collaborate with leaders in the oncology community and continuing our work to transform cancer care for patients.